Stable Cancer

Travel Insurance for Stable Cancer

"Stable cancer" covers a wide spectrum of situations — from a prostate cancer patient on active surveillance with no treatment, to someone with metastatic breast cancer whose disease is controlled on targeted therapy, to a follicular lymphoma patient on "watch and wait". What these situations share is that the cancer is not rapidly progressing and the person is living a relatively normal life.

What Does "Stable" Mean for Insurers?

Insurers assess stability through several lenses:

• No active aggressive treatment (no IV chemotherapy, no current radiotherapy course)
• No recent disease progression (last imaging shows no significant change)
• Medical team satisfied with current management
• Patient fit to travel in the opinion of their specialist

This is not a formal definition — insurers will form their own view based on the medical questionnaire answers. Providing supporting documentation from your specialist that uses the word "stable" is helpful.

Types of Stable Cancer Management

Active Surveillance (No Treatment)

Prostate cancer on active surveillance with regular PSA monitoring and periodic biopsies but no treatment is generally the most favourable stable cancer situation for travel insurance. There is no medication to manage and no active treatment, just monitoring. Most insurers will assess this favourably.

Hormone Therapy (Oral/Injectable)

Breast cancer on tamoxifen or aromatase inhibitors, prostate cancer on ADT, and similar hormone therapy situations are generally considered manageable. These are not aggressive systemic treatments and most insurers treat them comparably to management of other chronic conditions like hypertension.

Targeted Therapy (Daily Oral Tablets)

Patients on tyrosine kinase inhibitors, EGFR inhibitors, PARP inhibitors, or CDK4/6 inhibitors are on daily oral targeted therapy. This is generally assessed more favourably than IV chemotherapy. The insurer needs to understand what cancer is being treated, the current response, and that the disease is stable.

Immunotherapy (Ongoing Maintenance)

Some patients receive ongoing immunotherapy infusions as maintenance — for example, durvalumab maintenance after lung cancer treatment. This is more complex than oral targeted therapy but less so than active IV chemotherapy for progressive disease. Insurers will assess on a case-by-case basis.

Metastatic Cancer With Stable Disease

Stable metastatic cancer (cancer that has spread but is not actively progressing and is controlled on current treatment) is one of the more complex assessments. Some insurers will decline or exclude cancer-related cover; others will offer limited cover with a higher premium. Destinations with excellent oncology facilities are strongly advisable.

Destination Considerations for Stable Cancer

Stable cancer patients on ongoing treatment should prioritise destinations with accessible medical care:

• Australia: Best choice — excellent facilities, RHCA for emergency care, easy repatriation
• UK and Europe: Strong oncology capabilities, though RHCA does not apply to NZ residents
• Singapore and Japan: World-class facilities in Asia
• USA: Excellent facilities but very high costs — unlimited medical cover essential
• Pacific Islands: Limited facilities — medical evacuation insurance critical
• Remote areas globally: Evaluate carefully — proximity to appropriate specialist care is the key question

Medication Management While Travelling

For stable cancer patients on daily oral medication:

• Carry sufficient supply for the trip plus a buffer (minimum 2 weeks extra)
• Store medications as required (some targeted therapies require cool, dark storage)
• Carry in original pharmacy packaging with prescription labels
• Carry a physician's letter explaining the medication, dosage, and condition being treated
• Research availability at your destination in case of loss or damage

Key Takeaway

Stable cancer with ongoing management is generally assessable by NZ travel insurers. The specific management approach (active surveillance vs hormone therapy vs targeted therapy vs immunotherapy) significantly affects the assessment. Declare in full, get specialist support documentation, and compare multiple providers.